Patents by Inventor Brian Seed

Brian Seed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5656592
    Abstract: Disclosed is a method of reducing pain in a mammal involving administration of relaxin to the mammal.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: August 12, 1997
    Inventors: Brian Seed, John C. Seed
  • Patent number: 5547660
    Abstract: A nail polish composition with increased adhesiveness and durability is provided by the inclusion of compounds containing hydroxyl substituted aromatic groups, in particular protein-adherent polymers comprised of hydroxyl substituted aromatic groups.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: August 20, 1996
    Assignee: Advanced Genetic Technologies Corporation
    Inventors: John Seed, Brian Seed
  • Patent number: 5506126
    Abstract: A simple and highly efficient method for cloning cDNAs from mammalian expression libraries based on transient expression in mammalian host cells has been discovered. Novel expression vectors allowing highly efficient construction of mammalian cDNA libraries are disclosed. The cloning method of the invention which has been used to clone genes for cell surface antigens of human lymphocytes, has general application in gene cloning. Cell surface antigens cloned according to the present invention have been purified, and the nucleotide and amino acid sequences determined. These antigens have diagnostic and therapeutic utility in immune-mediated infections in mammals, including humans.
    Type: Grant
    Filed: October 18, 1993
    Date of Patent: April 9, 1996
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, Alejandro Aruffo
  • Patent number: 5420264
    Abstract: The present invention relates, in general, to substantially pure polynucleotide molecules specifying chimpanzee or rhesus monkey CD4, and fragments thereof and Gp120 binding molecules related to human CD4. The present invention further relates to polynucleotide molecules specifying CD4 fusion proteins and host cells containing the polynucleotide molecules.
    Type: Grant
    Filed: July 17, 1992
    Date of Patent: May 30, 1995
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, David Camerini
  • Patent number: 5411861
    Abstract: A novel rapid mutational analysis method for mapping protein epitopes is disclosed. This method has been used to identify the binding sites for 16 anti-CD2 and anti-CD4 monoclonal antibodies. The powerful, rapid, and simple method of the present invention allows isolation of a very large number of mutants, and is applicable to any intracellular or surface protein for which a cDNA and monoclonal antibodies are available. The present method is especially useful in ligand binding site studies for the design of new ligands and drugs.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: May 2, 1995
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, Andrew Peterson
  • Patent number: 5358857
    Abstract: Fusion proteins are obtained in high yields if a mixed oligonucleotide is constructed which codes for the ballast constituent of the fusion protein. The oligonucleotide mixture is introduced in a vector in such a manner that it is functionally linked to a regulatory region and to the structural gene for the desired protein. Appropriate host cells are transformed with the plasmid population obtained in this manner and the clones producing a high yield of coded fusion protein are selected.
    Type: Grant
    Filed: June 9, 1993
    Date of Patent: October 25, 1994
    Assignees: The General Hospital Corp., Hoechst Aktiengesellschaft
    Inventors: Siegfried Stengelin, Paul Habermann, Eugen Uhlmann, Brian Seed
  • Patent number: 5227293
    Abstract: Fusion proteins are obtained in high yields if a mixed oligonucleotide is constructed which codes for the ballast constituent of the fusion protein. The oligonucleotide mixture is introduced in a vector in such a manner that it is functionally linked to a regulatory region and to the structural gene for the desired protein. Appropriate host cells are transformed with the plasmid population obtained in this manner and the clones producing a high yield of coded fusion protein are selected.
    Type: Grant
    Filed: April 23, 1992
    Date of Patent: July 13, 1993
    Assignees: The General Hospital Corporation, Hoechst Aktiengesellschaft
    Inventors: Siegfried Stengelin, Wolfgang Ulmer, Paul Habermann, Eugen Uhlmann, Brian Seed
  • Patent number: 5081034
    Abstract: The invention relates to cloned genes, or degenerate variants thereof, which encode endothelial-leukocyte adhesion molecule-1 (ELAM-1), or fragments thereof. Such fragments may be leukocyte or complement-binding. The invention also relates to cloned genes encoding fusion proteins comprising ELAM. The invention also relates to vectors containing the cloned genes of the invention, hosts transformed with the vectors, and the protein products expressed therefrom. The invention also relates to pharmaceutical compositions comprising the expressed proteins. The invention also relates to methods for the treatment of inflammation, post reperfusion injury, bacterial infections, vasculitis, leukemia, and methods of inhibiting metastatic spread of tumor cells by administering the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: January 14, 1992
    Assignee: Brigham & Women's Hospital
    Inventors: Michael P. Bevilacqua, Michael A. Gimbrone, Brian Seed, Siegfried Stengelin